We are raising our Series A and actively seeking pharma partnerships, co-development opportunities, and strategic investors.
DotBio is raising USD 20M to advance DB007 to Phase I, validate our intracellular platform in animal models, and establish China presence. If you are a strategic investor or pharma partner, we'd love to connect.
Use of proceeds: DB007 → Phase I, DB009 intracellular validation, China IND development, platform expansion and BD.
Request Investor Deck →DotBio is always looking for talented and motivated scientists and business professionals. Send your CV to BD@dotbiopharma.com.